A randomized, double‐blind, placebo‐controlled phase 2 study of SHR‐1707, an anti‐amyloid‐β antibody, in patients with mild cognitive impairment and mild Alzheimer's disease

Abstract

Background: SHR‐1707 is a humanized IgG1 monoclonal antibody against amyloid‐β (Aβ). In vitro, SHR‐1707 displayed a similar affinity for Aβ fibrils and protofibrils, and a relatively higher affinity for Aβ monomers than lecanemab.

The paper